University of Pennsylvania
Dec 11, 2018
Notizia
Axovant tips nelotanserin from small molecule R&D Axovant has stopped nelotanserin development after it missed the primary endpoint in a phase 2 trial in patients with Lewy body dementia. The dull data compelled Axovant to miss the drug and finish its pivot from small molecules to gene therapies. The parent comp...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
